Cardinal Health (NYSE: CAH) received a significant boost in its price target from Argus, which increased the target from $211.00 to $232.00 in a report released on January 15, 2024. This adjustment comes as part of a broader positive outlook on the company’s performance, with Argus currently maintaining a buy rating on the stock.
Several other financial institutions have also revised their forecasts for Cardinal Health in recent weeks. Wells Fargo & Company raised its price target from $221.00 to $237.00, assigning the stock an “overweight” rating. Similarly, TD Cowen adjusted their target price from $183.00 to $225.00, also issuing a buy rating. Mizuho set a price target of $222.00, while Robert W. Baird established a more ambitious target of $250.00.
Overall, 14 analysts now rate Cardinal Health as a buy, with two analysts suggesting a hold. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $221.07.
Strong Financial Performance Drives Analyst Confidence
Cardinal Health recently reported its earnings for the fourth quarter on October 30, 2023. The company achieved earnings per share (EPS) of $2.55, surpassing analysts’ expectations of $2.22 by a notable $0.33. The firm also reported revenue of $64.01 billion, significantly exceeding the anticipated $59.41 billion.
The company’s net margin stood at 0.68%, with a negative return on equity of 84.37%. Year-over-year, Cardinal Health experienced a revenue increase of 22.4%, compared to $1.88 EPS during the same quarter last year. Looking forward, Cardinal Health has set its fiscal year 2026 guidance at $9.650 to $9.850 EPS, while analysts predict an average EPS of $7.95 for the current fiscal year.
Dividend Announcement and Institutional Activity
In addition to its strong earnings report, Cardinal Health announced a quarterly dividend of $0.5107, which was distributed on January 15, 2024. Shareholders recorded on January 2, 2024, received this payment, reflecting an annualized dividend of $2.04 and a yield of 1.0%. The company’s payout ratio is currently 30.77%.
Recent trading activity indicates strong institutional interest in Cardinal Health. Several hedge funds and institutional investors have adjusted their positions. Redhawk Wealth Advisors Inc. increased its holdings by 0.5%, now owning 9,255 shares valued at approximately $1.9 million. HF Advisory Group LLC also raised its stake by 0.9%, bringing its total to 5,227 shares worth around $1.07 million.
In total, institutional investors own 87.17% of Cardinal Health’s stock, reflecting strong confidence in the company’s future.
Headquartered in Dublin, Ohio, Cardinal Health has established itself as a leading provider of healthcare services and products since its inception in the 1970s. The company specializes in the wholesale distribution of pharmaceuticals, medical-surgical products, and logistics solutions, serving a wide range of healthcare providers, including hospitals and pharmacies.
As analysts maintain optimistic projections for Cardinal Health, the company’s performance will continue to be closely monitored by investors and market analysts alike.
